Editorial Commentary
Breakthroughs and challenges in the management of tropomyosin receptor kinase fusion-positive tumors
Abstract
The past decade has witnessed a paradigm shift in the treatment of cancer, moving from ‘one size fits all’ to a more precision medicine-based approach owing to the development of molecular diagnostic technologies capable of identifying an increasing number of actionable genomic alterations in the tumor tissue and circulating tumor DNA.
